Guardant Health’s Strong Growth Potential and Upward Trajectory Justifies Buy Rating

William Blair analyst Andrew Brackmann has reiterated their bullish stance on GH stock, giving a Buy rating today.

Andrew Brackmann has given his Buy rating due to a combination of factors that highlight Guardant Health’s strong growth potential. The company’s first-quarter performance demonstrated robust growth in both its oncology and screening segments, with oncology volumes accelerating for the third consecutive quarter and screening volumes exceeding expectations. This positive momentum is supported by a favorable valuation, as the stock trades at approximately seven times next-twelve-month revenue, comparable to other high-growth peers.
Moreover, Guardant Health’s revenue for the quarter surpassed consensus estimates by 7%, driven primarily by the oncology segment’s performance. The company’s full-year revenue guidance was also increased significantly, reflecting confidence in sustained growth. With key new oncology products and catalysts for the Shield platform expected to drive further growth, Brackmann sees multiple opportunities for the company to maintain its upward trajectory, justifying the Buy rating.

In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $60.00 price target.

Based on the recent corporate insider activity of 149 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year.